Fig. 25.1
(a–d) Parathyroid scintigraphy. (a) Planar image in early phase shows normal uptake of 99mTc sestamibi in the thyroid, submandibular glands, and heart. No abnormal uptake in the thoracic region is evident. The image acquired 2 h after intravenous administration (b) shows normal clearance of sestamibi from the thyroid without focus of radiotracer retention to suggest parathyroid disease. Thyroid scan (c), acquired after 99mTc-pertechnetate administration, does not reveal focal uptake or other abnormal findings. Progressive incremental subtraction scanning (d) performed by dedicated software confirmed absence of focal MIBI uptake suspicious for hyperfunctioning parathyroid gland(s)
Fig. 25.2
(a–d) Parathyroid scintigraphy. (a) In early phase, 99mTc-MIBI uptake is homogeneous within the thyroid gland that shows normal size and shape. Brown fat uptake is evident as physiological finding in pediatric patient. No abnormal uptake in the thoracic region is evident (b). Delayed image (c) shows regular washout of the tracer from the thyroid. Thyroid scan (d), acquired after 99mTc-pertechnetate administration, does not reveal focal uptake or other abnormal findings. Negative scintigraphic result rules out parathyroid hyperplasia
Fig. 25.3
(a–e) Parathyroid scintigraphy. (a) Early-phase 99mTc sestamibi image shows physiological uptake in salivary glands and thyroid gland, with focus of more intense uptake overlying inferior pole of left thyroid lobe. No other foci of abnormal uptake are evident in the thoracic region (b). Two-hour delayed image (c) shows regular washout of the tracer from thyroid parenchyma, but radiotracer retention in the area of focal uptake detected in the early image and not detectable in thyroid scintigraphy (d). Computed subtraction scanning performed by dedicated software (e) confirmed the presence of focal MIBI uptake suspicious for hyperfunctioning parathyroid gland
